www.fdanews.com/articles/81483-abbott-labs-shares-seen-as-overvalued
ABBOTT LABS SHARES SEEN AS OVERVALUED
October 7, 2005
UBS Investment Research initiated coverage of Abbott Laboratories with a "reduce" rating and $37 target price.